Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV.
Pere DomingoFrancesc VillarroyaMarta GiraltJoan Carles DomingoPublished in: International journal of obesity (2005) (2020)
Exposure to some antiretroviral drugs, especially integrase strand transfer inhibitors (INsTI)-based combination antiretroviral therapy (cART) has been associated with weight gain in people living with HIV (PLWH) exceeding what would be a "return to health" phenomenon. Notwithstanding the fact that weight gain and obesity are multifactorial, the common epidemiological link in PLWH is INsTI-based cART. Here, we postulate that interference with the melanocortin system (MCS) functioning by INsTI plays an essential role in excess weight gain and obesity in PLWH, similar to disturbances caused by melanocortin receptor (MCR) mutations in the general population and by antipsychotic therapy in psychiatric patients.
Keyphrases
- weight gain
- hiv infected
- body mass index
- antiretroviral therapy
- birth weight
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv positive
- end stage renal disease
- weight loss
- mental health
- ejection fraction
- escherichia coli
- healthcare
- newly diagnosed
- chronic kidney disease
- public health
- prognostic factors
- type diabetes
- peritoneal dialysis
- metabolic syndrome
- men who have sex with men
- stem cells
- hepatitis c virus
- insulin resistance
- physical activity
- south africa
- skeletal muscle
- mesenchymal stem cells
- social media
- cell therapy
- health promotion